Abstract:Ying-Hua Luo, 1, &ast Cheng Wang, 2, &ast Wan-Ting Xu, 3, &ast Yu Zhang, 3 Tong Zhang, 3 Hui Xue, 3 Yan-Nan Li, 3 Zhong-Ren Fu, 3 Ying Wang, 4 Cheng-Hao Jin 3– 5 1 Department of Grass Science, College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing, 163319, People's Republic of China; 2 Pharmacy Department, Daqing Oilfield General Hospital, Daqing, 163001, People's Republic of China; 3 Department of Biochemistry and Molecular Biology, College of Life Science & Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319, People's Republic of China; 4 College of Food Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, 163319, People's Republic of China; 5 National Coarse Cereals Engineering Research Center, Daqing, 163319, People's Republic of China &astThese authors contributed equally to this work Correspondence: Cheng-Hao Jin; Ying Wang Email ; Background: 18β-glycyrrhetinic acid (18β-Gly), which is extracted from licorice root, has various pharmacological properties; however, its anti-cancer effects on lung cancer cells have not been fully established. Purpose: In this study, we investigated the underlying molecular mechanisms of 18β-Gly. Results: Our results showed that 18β-Gly had significant cytotoxic effects and no apparent side effects. 18β-Gly induced mitochondria-dependent apoptosis of A549 lung cancer cells. In addition, after treatment with 18β-Gly, intracellular reactive oxygen species (ROS) levels were significantly increased, and G2/M cell cycle arrest and inhibition of cell migration were induced via the mitogen-activated protein kinase (MAPK)/signal transducer and activator of transcription 3 (STAT3)/nuclear factor kappa (NF-κB) signaling pathways. After pretreatment with the ROS scavenger N-acetyl-L-cysteine or MAPK inhibitors, the expression levels of phosphorylated p38 (p-p38), phosphorylated c-Jun N-terminal kinase, inhibitor of nuclear factor kappa B, cleaved caspase-3 (cle-cas-3), cleaved poly (ADP ribose) polymerase (cle-PARP), p-p53, p27, p21, and E-cadherin were decreased; and levels of phosphorylated extracellular signal-regulated kinase, p-STAT3, NF-κB, Bcl-2, cyclin B1, cyclase-dependent kinase 1/2 (CDK1/2), N-cadherin, vimentin, and snail homolog 1 (SNAI 1) were increased. In addition, the percentage of cells in the G2/M phase was decreased, and inhibition of migration was reduced. Conclusion: In summary, 18β-Gly induced apoptosis and G2/M cell cycle arrest and inhibited migration via the ROS/MAPK/STAT3/NF-κB signaling pathways in A549 lung cancer cells. Therefore, 18β-Gly is a novel promising candidate for the treatment of lung cancer. Keywords: 18β-glycyrrhetinic acid, lung cancer, apoptosis, cell cycle arrest, ROS, cell migration Lung cancer is one of the most common malignant tumors, with a morbidity and mortality that has rapidly increased globally in recent decades. 1 Despite advances in early detection and treatment strategies for lung cancer, the 5-year survival rate is still below 20%. 2 Treatment options for lung cancer included surgery, chemotherapy, radiation therapy, or a combination. In addition, systemic chemotherapy is commonly used to treat advanced lung cancer by controlling symptoms and prolonging survival. 3 Despite improved chemotherapy, long-term survival in patients with advanced lung cancer remains low. 4 Therefore, it is important to study the pathogenesis and molecular mechanisms of lung cancer, and to identify novel therapeutic drugs with high anti-cancer efficacy and few side effects. In recent years, natural compounds derived from traditional Chinese medicines have become a research hotspot in the development of highly effective anti-cancer drugs with few side effects. 5,6 18β-glycyrrhetinic acid (18β-Gly) is the major bioactive component of Glycyrrhizae Radix, possessing antiulcerative, anti-inflammatory, and antiproliferative properties. 7–9 In addition, 18β-Gly inhibits migration and invasion via the reactive oxygen species (ROS)/protein kinase C-alpha/ERK pathways in human gastric cancer cells. 10 However, to date, the effects of 18β-Gly on lung cancer remain unclear. ROS, mainly produced by mitochondria, play an important role in various signaling pathways. 11 Most research has focused on the regulatory relationship between ROS and downstream signaling pathways. 12,13 Mitogen-activated protein kinase (MAPK) and p53 are two important downstream molecules regulated by ROS, and are involved i -Abstract Truncated-

Pyrogallol Suppresses the Tumor Progression via Modulating Aerobic Glycolysis and STAT2 Signaling Pathway in Non-small Cell Lung Carcinoma

Pyrogallol promotes growth arrest by activating the p53-mediated up-regulation of p21 and p62/SQSTM1-dependent degradation of β-catenin in nonsmall cell lung cancer cells

Identification of Glycogen Phosphorylase L As a Potential Target for Lung Cancer

The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells

Codonopsis pilosula polysaccharide suppresses the progression of non-small cell lung cancer by triggering NLRP3/GSDMD-dependent pyroptosis

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Procyanidins Mediates Antineoplastic Effects Against Non-Small Cell Lung Cancer Via the JAK2/STAT3 Pathway

18β-Glycyrrhetinic Acid Has Anti-Cancer Effects via Inducing Apoptosis and G2/M Cell Cycle Arrest, and Inhibiting Migration of A549 Lung Cancer Cells

Acovenosigenin A β-glucoside mediates JAK2-STAT3 signaling pathway by targeting GP130 in A549 and H460 cells based on integrative analysis of transcriptome and proteome and biological verification

Prostaglandin 15d-PGJ2 inhibits proliferation of lung adenocarcinoma cells by inducing ROS production and activation of apoptosis via sirtuin-1

Exploring the effect of epigallocatechin gallate on non small cell lung cancer

Proteasome Inhibitor Ysy01a Abrogates Constitutive Stat3 Signaling Via Down-Regulation of Gp130 and Jak2 in Human A549 Lung Cancer Cells

Novel Perbutyrylated Glucose Derivatives of (–)-Epigallocatechin-3-Gallate Inhibit Cancer Cells Proliferation by Decreasing Phosphorylation of the EGFR: Synthesis, Cytotoxicity, and Molecular Docking

Simultaneous suppression of PKM2 and PHGDH elicits synergistic anti-cancer effect in NSCLC

Unveiling the therapeutic potential of epigallocatechin gallate in liver cancer: insights from network pharmacology and in vitro assays

Abstract 2255: Distinct Biological Effect of Inhibiting the Metabolic Pathway Using Active Compounds Derived from Chinese Medicinal Herbs in Non-Small Cell Lung Cancer Cells with Different EGFR Mutational Profiles.

cyy-287, a novel pyrimidine-2,4-diamine derivative, inhibits tumor growth of EGFR-driven non-small cell lung cancer via the ERK pathway

Trichosanthin inhibits cell growth and metastasis by promoting pyroptosis in non-small cell lung cancer

Ginsenoside Rh2 Inhibits Glycolysis through the STAT3/c-MYC Axis in Non-Small-Cell Lung Cancer

Grape Proanthocyanidins Induce Apoptosis by Loss of Mitochondrial Membrane Potential of Human Non-Small Cell Lung Cancer Cells In Vitro and In Vivo

Regulator of G Protein Signaling 20 Contributes to Radioresistance of Non-Small Cell Lung Cancer Cells by Suppressing Pyroptosis